Sirolimus for Injection (Albumin-bound)
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Sirolimus for Injection (Albumin-bound) is one of 43 small molecule programs targeting Epithelioid Hemangioendothelioma. It is currently in Phase 3.
2
Indications
7
Total Trials
4
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Sirolimus for Injection (Albumin-bound)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Breast Cancer2 trials
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Active, not recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolledPEComa1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details